Personalis Inc. (Nasdaq: PSNL)

https://www.personalis.com

LinkedIn: https://www.linkedin.com/company/personalis-inc

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. *

	Start	2014-04-24 existent
	Group	Personalis (Group)
	Industry	genomic services
	Industry 2	personalised medicine / precision medicine

	Region	Menlo Park, CA
	Country	United States (USA)
	Street	1330 O’Brien Drive
	City	94025 Menlo Park, CA
	Tel	+1-650-752-1300
		Address record changed: 2023-03-09

Basic data	Employees	n. a.

		* Document for »About Section«: Personalis, Inc.. (3/7/23). "Press Release: Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay". Fremont, CA.

		Record changed: 2026-05-02

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

More documents for Personalis (Group)

[1] Personalis, Inc.. (3/7/23). "Press Release: Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay". Fremont, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)